Long Zheng is a scientist at Bristol-Myers Squibb, specializing in bioassay development for biologics potency strategy. With a background in pharmaceutical engineering and a Ph.D. in molecular biology, he has extensive experience in designing, optimizing, and validating bioassays to support drug development and regulatory submissions. Currently, long focuses on multiplexed target binding method development, ensuring the accuracy and consistency of potency assessments for biologics.
Before joining BMS, he gained over 8 years research experience in antibody engineering and cell therapy. His expertise spans data science, oncology, and immunology, with a strong emphasis on method development and troubleshooting. Long is passionate about bridging scientific innovation with practical application and advancing technologies to drive the development of safe and effective therapeutics.